The suitability of younger patients with prostate cancer (PCa) for initial active surveillance (AS) has been questioned on the basis of eventual treatment necessity and concerns of safety; however, the role of age on surveillance outcomes has not been well defined.
INTRODUCTION
Active surveillance (AS), a management strategy consisting of close, periodic disease observation with the opportunity for delayed definitive therapy with curative intent, has been advanced as a means to reduce overtreatment in men with low-risk prostate cancer (PCa) without compromising oncologic safety. 1 The feasibility of AS has been demonstrated in several prospectively followed cohorts with extended follow-up in which treatment-free rates and preservation of health-related quality of life (HRQOL) remain high, with favorable cancer-specific survival. [2] [3] [4] [5] Despite historical patterns indicating high rates of initial primary treatment of patients with lowrisk disease, recent longitudinal trends in the United States show increasing use of AS after diagnosis to nearly 40%. 6, 7 The suitability of younger patients for initial management with AS has received limited study and has been questioned because of concerns for patient safety, a longer burden of follow-up, and the perception that definitive treatment will eventually be needed. Although not always used as a firm criterion for enrollment in large, prospective AS cohort studies or in practice guidelines, patient age empirically serves as a major driver in the decision to pursue surveillance or immediate definitive therapy, favoring early treatment in younger individuals. 8, 9 Yet, population-level analyses indicate that increasing age at diagnosis is an independent risk factor for Author affiliations and support information (if applicable) appear at the end of this article.
PCa-specific mortality. 10 Moreover, younger patients have higher baseline sexual and urinary function scores at the time of diagnosis and, therefore, stand to lose the most by immediate treatment.
11
From this context, we aimed to investigate the role of patient age on outcome by examining rates of disease reclassification over time, selection of definitive treatment, and long-term biochemicalfree survival outcomes among individuals receiving delayed prostatectomy in a large cohort of men managed with AS at a tertiary referral center.
MATERIALS AND METHODS
Under institutional review board approval, we identified patients within the Urological Oncology Database at the University of California San Francisco (UCSF), a prospectively accrued registry, including a large cohort of men managed with surveillance for PCa. We retrospectively identified all consenting individuals electing AS at our institution, beginning in 1992, with a minimum follow-up of 6 months from the time of initial diagnostic biopsy (Appendix Fig A1, online only). Most men (66%) elected AS in the context of strict institutional criteria, including Gleason score # 3+3, prostate-specific antigen (PSA) concentration at diagnosis # 10 ng/mL, clinical stage # T2, # 33% biopsy-specimen cores involved with cancer, and no single core with . 50% cancer. In addition, men with otherwise favorable low-and intermediate-risk disease were selectively enrolled in AS on the basis of their preferences. Age has not been an explicit criterion for AS eligibility.
The recommended AS protocol included PSA testing at 3-month intervals and confirmatory biopsy within 12 months, followed by periodic transrectal ultrasound-guided surveillance biopsy procedures every 12 to 24 months based on clinical risk and observed disease trajectory. Specimens obtained during diagnostic biopsies performed at referring institutions were reviewed by experienced genitourinary pathologists, and surveillance biopsies consisted of extended octant sampling including a minimum of 12 cores. Indications for recommending definitive treatment included clinical progression, defined on the basis of increasing Gleason grade, tumor volume, PSA level, clinical stage, patient anxiety, or patient preference. The date of diagnosis was recorded as the date of first positive biopsy specimen at any institution, which was recorded as the time of enrollment. Duration of follow-up was calculated from the date of diagnosis to the date of last contact.
The primary study objective was to evaluate the association of younger patient age with biopsy-based Gleason score upgrade, defined as any increase in Gleason score to 3+4 or higher. Secondary study end points included any biopsy-determined progression (upgrade or tumor volume to . 33% positive cores), rates of definitive treatment, and biochemical recurrence (BCR) after delayed radical prostatectomy (RP), defined as two consecutive PSA values . 0.2 ng/mL or receipt of salvage therapy in the setting of a detectable PSA level. Age at diagnosis was examined as a continuous variable (per decreasing 1 year), and dichotomized as # 60 years versus older than 60 years based on a putative threshold for clinical practice near the median age of the study population.
We described age, race/ethnicity, relationship status, PSA concentration, clinical T stage, number of biopsy-specimen cores sampled, and number of biopsy-specimen cores positive for cancer, prostate volume, and Gleason score at enrollment, using frequency tables, means, and medians. To account for anticipated differences in sampling that may occur due to age-related differences in prostate volume, log-transformed PSA density was included a priori in multivariable analyses. Pearson x 2 and analysis of variance comparisons were used for categorical and continuous variables, respectively. Clinical risk was calculated using the Cancer of the Prostate Risk Assessment (CAPRA) score and grouped as low (0-2), intermediate (3) (4) (5) , or high (6-10), as previously described.
12 Pathologic characteristics at delayed prostatectomy were compared using the postsurgical CAPRA instrument, CAPRA-S. 13 Life tables, Kaplan-Meier curves, and the log-rank test were used to examine the unadjusted effect of older age on the outcomes of biopsybased Gleason score upgrade, biopsy-determined progression, definitive treatment, and BCR after delayed RP. Multivariate Cox proportional hazards regression models were used to examine the association of age, adjusted for relevant clinical and demographic characteristics on the outcomes of biopsy-based Gleason score upgrade and biopsy-determined progression. Multivariate model fit based on the exclusion of (null model) or inclusion (final model) of age as a covariate was assessed using Bayesian information criteria. To adjust for referral to our institution, site of diagnosis (UCSF v referring provider) was used as a covariate in the multivariable models. The end points of biopsy-based Gleason score upgrade, biopsy-determined progression, and definitive treatment were evaluated from the date of first diagnosis until event occurrence or last follow-up. Subjects were censored at the time of treatment for the outcomes of biopsy-based Gleason score upgrade and biopsy-determined progression. Among those patients ultimately treated with RP, time to BCR was calculated from date of prostatectomy to event or last follow-up and censored at the time of salvage treatment (in response to or in the absence of progression) or death as the result of any cause. To account for differences in baseline clinical-risk profiles among younger and older patients, sensitivity analyses were performed within a restricted population of patients meeting strict criteria for AS, as defined previously in this section, to examine clinical outcomes. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
We identified 1,433 patients managed with AS; they were followed for a median of 49 months (interquartile range [IQR] , 26 to 80 months). The median age at enrollment was 63 years (IQR, 57 to 68 years), including 599 patients (42%) # 60 years old and 834 (58%) . 60 years old. Gleason score at diagnosis was # 3+3 in 1,258 patients (89%) and 3+4 in 137 (10%). Compared with men . 60 years old, younger patients had lower PSA level at diagnosis (median, 5.0 ng/mL v 5.6 ng/mL; P , .01), a tumor that was more frequently of Gleason pattern 3+3 (93% v 85%; P , .01), and more frequently a low CAPRA risk classification (87% v 78%; P , .01). Younger patients underwent more surveillance biopsy procedures (median, 3 v 2; P , .01) and had similar numbers of PSA tests (median, 10 v 9; P = .27). Most patients (74%) were referred by an external institute to UCSF after a diagnosis of PCa, and 26% were diagnosed internally (Appendix Table A1 , online only). Clinical and demographic characteristics at diagnosis are listed in Table 1 and participant allocation is explained in Appendix Figure A1 .
Unadjusted Gleason score upgrade-free rates for men # 60 years old compared with men older than 60 years were 73% versus 64%, respectively, at 3 years of follow-up and 55% versus 48%, respectively, at 5 years (P , .01). When examined by decade at diagnosis, younger patients also had lower unadjusted rates of biopsy-based Year of diagnosis, biopsy-specimen Gleason score, percentage of positive biopsy-specimen cores, PSA density, referral status, and number of total biopsy procedures were also significantly associated with time to biopsy-based Gleason score upgrade and progression (Table 2) . Moreover, age group (# 60 years v older than 60 years) was independently associated with decreased risk of biopsy-based Gleason score upgrade (HR, 0.67 [95% CI, 0.55 to 0.83]; P , .01) and biopsy-determined progression (HR, 0.78 [95% CI, 0.65 to 0.92]; P , .01; data not shown). Multivariate models incorporating age demonstrated marginally better fit for the outcomes of biopsy-based Gleason score upgrade and biopsydetermined progression.
Rates of definitive treatment were similar among age groups. For men # 60 years versus those older than 60 years, treatmentfree survival rates were 78% versus 74%, respectively at 3 years and 65% versus 64%, respectively at 5 years (log-rank P = .84). Among individuals ultimately undergoing definitive treatment, a larger proportion of older patients received radiation therapy than younger patients (38% v 21%) and fewer received RP (58% v 78%; P , .01 for both. At the extremes of age, the 5-year treatment-free survival was 60% for men # 50 years old at diagnosis compared with 71% for those $ 70 years (Appendix Fig A4, online only) . In Cox proportional hazards regression models adjusted for clinical and pathologic characteristics, age at diagnosis was not associated with receipt of definitive treatment (HR per 1-year decrease, 1.000 [95% CI, 0.987 to 1.013]; P = 0.98; Table 3 ).
A total of 320 men (22%) underwent delayed treatment with RP. A total of 206 mean (64%) were treated after progression as determined from evaluation of biopsy specimen, 10 (3%) with a PSA doubling time , 36 months, and 20 (6%) who were categorized as at intermediate clinical risk at diagnosis. Eighty-four men (26%) were treated in the absence of PSA or biopsydetermined progression, including 20 who did not undergo a second biopsy before RP. Median follow-up among men treated with prostatectomy was 41 months (IQR, 24-81 months). On unadjusted analysis, pathologic T stage (P = .42), Gleason score (P = .10), lymph node status (P = .40), and CAPRA-S score (P = .42) were similar between men # 60 years old and those older than 60 years. In Cox proportional hazards regression models, younger age at diagnosis Table 3 ). These relationships also remained significant at a cutoff age of 60 years. Age group was not significantly associated with time to treatment (HR, 0.992 [95% CI, 0.976 to 1.009]; P = .36) or BCR after RP (HR, 0.972 [95% CI, 0.852 to 1.018]; P = .67). Furthermore, the addition of age as a variable did not improve model performance for the outcomes of time to treatment or recurrence.
DISCUSSION
Younger men who are diagnosed with PCa report higher baseline urinary and sexual quality of life and, in light of favorable anticipated longevity, may endure a longer detriment to HRQOL with definitive treatment.
11,14,15 Although younger patients may fare reasonably well, given their high baseline level of functioning if they undergo well-performed primary treatment, some decline in function is not uncommon, and at least a transient decline is nearly universal. AS represents a potential strategy to avoid or delay treatment in younger patients with otherwise favorable-risk disease. Yet uncertainty remains about the appropriateness of surveillance in younger patients because of potential risks of missed opportunities for cure. 16 With the present duration of follow-up, this study is, to our knowledge, the largest and most comprehensive study to explicitly address the role of patient age at diagnosis with outcome during AS. Among 1,433 men, younger patient age was associated with decreased risk of biopsy-based Gleason score upgrade and biopsy-determined progression, yet with similar rates of definitive treatment during follow-up.
PCa incidence and lethality are age-related phenomena.
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Although older patients possess comparatively higher burdens of advanced or metastatic disease at presentation, our study population represented a cohort in which inclusion was restricted to those with favorable disease characteristics. Indeed, 66% of our cohort elected to pursue AS in the setting of strict clinical criteria and otherwise possessed low-risk and low-intermediate-risk disease. When restricted to patients meeting more restrictive eligibility criteria, the associations with age remained similar; age remained a significant independent predictor of biopsy-based Gleason score upgrade and progression but was not associated with time to treatment or subsequent clinical recurrence after delayed RP. In this analysis, our findings are also consistent with a broader body of literature that has identified clinical parameters associated with disease reclassification over time, including age, PSA density, and tumor characteristics at diagnosis.
17-19
The associations of age and AS outcomes in our series are in agreement with other surveillance cohorts.
2,19-21 Anderson et al 22 examined the role of patient age on Gleason score upgrading at confirmatory biopsy within a cohort of men with initial biopsy Gleason score # 3+3 and clinical stage # T2a, where older patient age was associated with increased risk of Gleason score upgrading. Notably, however, in our analysis, the risk of biopsy-determined progression persisted over time, suggesting that this may not be limited to a phenomenon of misclassification on evaluation of diagnostic biopsy specimens alone. Refined biopsy strategies, including magnetic resonance-fusion guidance, may improve the accuracy of initial sampling and may affect the rates of disease reclassification over time. A large prospective study would be required to answer this question definitively.
23,24
Despite attempts to standardize AS protocols, considerable variation exists in the practice of, and compliance with, surveillance. 25 Perhaps reflecting greater concern for disease control and the possibility of biopsy undersampling, younger patients have been shown to undergo greater degrees of AS intensity. 26 Indeed, in our cohort, men # 60 years old underwent more surveillance biopsy procedures than men older than 60 years within the same interval. From this perspective, the lower risks of progression despite greater scrutiny (ie, an approximately 30% lower risk of upgrading over time) should be informative to counsel younger patients with low-risk PCa who are considering initial management with surveillance. Furthermore, we anticipate that the dynamics of biopsy-determined progression may vary as our contemporary surveillance population ages. For example, detection of disease reclassification via biopsy specimen may decline in older patients in later decades of life because of competing medical comorbidities and decreasing intensity of surveillance. Moreover, reclassification after multiple biopsy procedures does occur; however, it is less common than at earlier periods of surveillance. 27 Accordingly, for men diagnosed at younger ages, a relatively longer horizon of surveillance may offer a greater opportunity for disease progression.
There are limitations in this study that merit discussion. First, although a formal surveillance protocol is offered at our institution, strict adherence has not been enforced, owing to patient preference as well as an evolving, risk-adapted approach with the intention of limiting the biopsy burden for those with low risk of progression. 28 As a consequence, it is conceivable that missing data and limited follow-up did not occur randomly and might favor inclusion of individuals with higher-risk features or those whose disease has progressed, as determined by evaluation of biopsy specimens. In addition, most of the study cohort underwent a diagnostic biopsy procedure at an outside institution, where younger patients more likely to be referred. Although we attempted to adjust for referral status, the influence of unmeasured biases not fully accounted for in these methods may limit the generalizability of the study results outside of academic referral institutions. Furthermore, we used biopsy-based Gleason score upgrade and biopsy-determined progression, defined by a change in tumor volume, as study end points for surveillance. Although the detection of higher Gleason-pattern disease in subsequent biopsy specimens is often a triggering event for definitive treatment, Abbreviations: AS, active surveillance; HR, hazard ratio; PSA, prostate-specific antigen; RP, radical prostatectomy; UCSF, University of California, San Francisco.
jco.org a small proportion of patients within our cohort have opted for continued AS. 29 We also noted that younger patients exhibited relatively lower-risk disease profiles compared with older men, and were more likely to have an initial diagnosis outside of our institution-both factors that may introduce unmeasured biases that may impact the perceived risks of progression over time. Last, because patients were identified from a departmental database, it is possible that a few patients receiving PCa care through other disciplines may not have been captured in this analysis.
The relative contributions of biopsy undersampling versus disease progression during surveillance remain unclear. 30 This may be particularly relevant to the issue of age, because older patients tend to have a larger prostate volume that may lead to sampling biases on systematic biopsy. 4 However, the observation that observed age-related differences persisted after adjustment for PSA density suggests that prostate volume did not greatly influence our results. Other limitations include the length of follow-up after prostatectomy that may underestimate the rates of recurrence. Furthermore, our analysis lacks complete longitudinal HRQOL data, which prevented a direct comparison of urinary, sexual function, and psychologic outcomes by age. In light of multicenter studies indicating better preservation of urinary and sexual function among men managed with AS, as compared with those receiving definitive treatment, an opportunity also exists to examine these outcomes by age.
31
Overtreatment of low-risk prostate cancer remains a major driver of the controversy surrounding PSA-based early detection efforts, and the use of AS as the preferred initial management strategy for most men with low-risk disease is a critical component of screening practices. 32 Although there is no consensus on the optimal screening approach, a growing body of literature supports obtaining an initial baseline screening at a young age-as young as 45 years old-and basing subsequent screens on this initial result.
33
Such an approach is supported by robust biologic and epidemiologic rationales and has been endorsed by the National Comprehensive Cancer Network. 34 However, men in their 40s and 50s cannot reasonably be offered PSA testing unless they also will be offered AS if low-risk cancer is identified. Treatment decisions should be consistently driven by disease characteristics, overall life expectancy, and patient preferences rather than by chronological age.
In conclusion, among 1,433 men with clinical low-and intermediate-risk PCa, younger patient age was independently associated with decreased risk of biopsy-based Gleason score upgrade and progression. Nevertheless, the rates of definitive treatment were similar among older and younger patients. Men # 60 years old received subsequent RP more often than radiation therapy. Among men treated with delayed prostatectomy, age was not significantly associated with the risk of biochemical failure. At diagnosis, appropriately risk-stratified patients may be counseled that in the short to intermediate term, younger age was not associated with worse surveillance outcomes assessed by biopsy outcome and recurrence-free survival after delayed treatment. Longer follow-up is needed to assess more distant outcomes. 
